Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

iBio Initiates Non-human Primate Study For Its Activin E Engineered Antibody Candidate, Now Named IBIO-610. This Preclinical Study Will Evaluate The Pharmacokinetics And Early Signs Of Efficacy Of IBIO-610 In Obese And Elderly NHPs, Including Its Impact On Fat And Body Composition

Author: Benzinga Newsdesk | June 16, 2025 07:06am

iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody
New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess early signs of efficacy on fat reduction and body composition
Mouse study shows IBIO-610 alone drives an overall body weight loss of 8.9%*, and prevents weight regain following GLP-1 treatment in obese mice, results of which will be presented at ADA on Monday June 23rd

Posted In: IBIO